Exact Mass: 469.2100416
Exact Mass Matches: 469.2100416
Found 116 metabolites which its exact mass value is equals to given mass value 469.2100416
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
20-COOH-leukotriene E4
C23H35NO7S (469.21341200000006)
20-COOH-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-COOH-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)
2-Methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide
latrunculol B
C23H35NO7S (469.21341200000006)
A natural product found in Cacospongia mycofijiensis.
Ala Gly His Trp
C22H27N7O5 (469.20735720000005)
Ala Gly Trp His
C22H27N7O5 (469.20735720000005)
Ala His Gly Trp
C22H27N7O5 (469.20735720000005)
Ala His Trp Gly
C22H27N7O5 (469.20735720000005)
Ala Trp Gly His
C22H27N7O5 (469.20735720000005)
Ala Trp His Gly
C22H27N7O5 (469.20735720000005)
Glu Pro Pro Gln
Glu Pro Gln Pro
Glu Gln Pro Pro
Gly Ala His Trp
C22H27N7O5 (469.20735720000005)
Gly Ala Trp His
C22H27N7O5 (469.20735720000005)
Gly His Ala Trp
C22H27N7O5 (469.20735720000005)
Gly His Trp Ala
C22H27N7O5 (469.20735720000005)
Gly Trp Ala His
C22H27N7O5 (469.20735720000005)
Gly Trp His Ala
C22H27N7O5 (469.20735720000005)
His Ala Gly Trp
C22H27N7O5 (469.20735720000005)
His Ala Trp Gly
C22H27N7O5 (469.20735720000005)
His Gly Ala Trp
C22H27N7O5 (469.20735720000005)
His Gly Trp Ala
C22H27N7O5 (469.20735720000005)
His Trp Ala Gly
C22H27N7O5 (469.20735720000005)
His Trp Gly Ala
C22H27N7O5 (469.20735720000005)
Pro Glu Pro Gln
Pro Glu Gln Pro
Pro Pro Glu Gln
Pro Pro Gln Glu
Pro Gln Glu Pro
Pro Gln Pro Glu
Gln Glu Pro Pro
Gln Pro Glu Pro
Gln Pro Pro Glu
Trp Ala Gly His
C22H27N7O5 (469.20735720000005)
Trp Ala His Gly
C22H27N7O5 (469.20735720000005)
Trp Gly Ala His
C22H27N7O5 (469.20735720000005)
Trp Gly His Ala
C22H27N7O5 (469.20735720000005)
Trp His Ala Gly
C22H27N7O5 (469.20735720000005)
Trp His Gly Ala
C22H27N7O5 (469.20735720000005)
20-COOH-leukotriene E4
C23H35NO7S (469.21341200000006)
20-carboxy-LTE4
C23H35NO7S (469.21341200000006)
CP-724714
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163760 - HER2-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159156 - HER2 Inhibitor
5-TBDMS-Bz-dA
5'-O-TBDMS-Bz-dA is a nucleoside with protective and modification effects.
4H-1,2,4-Triazole, 3-(4-(3-(ethylsulfonyl)propyl)bicyclo(2.2.2)oct-1-yl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-
C23H30F3N3O2S (469.20107160000003)
(6Z,9Z,11E,13E,15R,16S)-15-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-16-hydroxyicosa-6,9,11,13-tetraenedioic acid
C23H35NO7S (469.21341200000006)
1-(1-tert-butyl-5-tetrazolyl)-N-(2-furanylmethyl)-N-(phenylmethyl)-1-[4-(trifluoromethyl)phenyl]methanamine
C25H26F3N5O (469.20893420000004)
N-[(2R,4aS,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(2S,4aR,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
(1S,9R,10R,11R)-5-(cyclohexen-1-yl)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-12-methyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[(2S,4aS,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(2S,4aR,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(2R,4aR,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
N-[(2R,4aS,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
2-[(1R,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1R,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1R,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1S,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
N-[(2S,4aS,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
(3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid
C25H31N3O4S (469.20351660000006)
[(1R)-7-methoxy-9-methyl-1-(3-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
2-[(1S,3S,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1S,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1S,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
2-[(1R,3S,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
C25H28FN3O5 (469.20128900000003)
(3S)-4-[3-(1-cyclohexenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-2-methylsulfonyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
C25H31N3O4S (469.20351660000006)
N-[(2R,4aR,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
C25H28FN3O5 (469.20128900000003)
(1R,9S,10S,11S)-5-(cyclohexen-1-yl)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-12-methyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[(1S)-7-methoxy-2-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
[(1R)-7-methoxy-2-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
2-(dimethylamino)-1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-(2-thiazolylmethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
2-(dimethylamino)-1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-(2-thiazolylmethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
[(1S)-7-methoxy-9-methyl-1-(3-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
[(1S)-7-methoxy-9-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C25H31N3O4S (469.20351660000006)
2-Amino-3-[(2-heptanoyloxy-3-hexanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
C19H36NO10P (469.2076726000001)
2-Amino-3-[hydroxy-(2-octanoyloxy-3-pentanoyloxypropoxy)phosphoryl]oxypropanoic acid
C19H36NO10P (469.2076726000001)
2-Amino-3-[(3-butanoyloxy-2-nonanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
C19H36NO10P (469.2076726000001)
2-Amino-3-[(2-decanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
C19H36NO10P (469.2076726000001)
3-[(3-Acetyloxy-2-undecanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid
C19H36NO10P (469.2076726000001)
20-carboxyleukotriene E4
C23H35NO7S (469.21341200000006)
A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding carboxylic acid.
(1s,2r,3s,4r,4ar,8as)-2,3-dihydroxy-3,4,8,8a-tetramethyl-4-[(2s)-6-oxo-2h,3h,4h-furo[2,3-c]furan-2-yl]-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl pyridine-3-carboxylate
(1'r,2r,9r,9as,12'r)-15'-hydroxy-12'-methyl-2-(2-methylpropyl)-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione
2,3-dihydroxy-3,4,8,8a-tetramethyl-4-{6-oxo-2h,3h,4h-furo[2,3-c]furan-2-yl}-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl pyridine-3-carboxylate
15'-hydroxy-12'-methyl-2-(2-methylpropyl)-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione
8,17-dihydroxy-17-(2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl)-9-methoxy-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one
C23H35NO7S (469.21341200000006)
ethyl 4-oxo-4-[(9s)-4,5,15,16-tetramethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaen-10-yl]butanoate
(1r,4z,8s,9s,10z,12s,15r,17r)-8,17-dihydroxy-17-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]-9-methoxy-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one
C23H35NO7S (469.21341200000006)